Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancer

22 Dec 2022

Abstract excerpt

Enhancer of zeste homolog 2 (EZH2) is a significant epigenetic regulator that plays a critical role in the development and progression of cancer. However, the multiomics features and immunological effects of EZH2 in pan-cancer remain unclear. Transcriptome and clinical raw data of pan-cancer samples were acquired from The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases, and subsequent data...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Epigenetics and DNA Methylation
Share to Ferroptosis and cancer prognosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36545914
DOI: 10.1042/bsr20222230

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Multiomics characteristics and immunotherapeutic potential of EZH2 in pan-cancerPMID 36545914Read ↗

EZH2 in Cancer Progression and Potential Application in Cancer Therapy: A Friend or Foe?Semantic proximity Read ↗

EZH2 abnormalities in lymphoid malignancies: underlying mechanisms and therapeutic implications.Semantic proximity Read ↗

Combining EZH2 inhibitors with other therapies for solid tumors: more choices for better effectsSemantic proximity Read ↗

EZH2-associated tumor malignancy: A prominent target for cancer treatment.Semantic proximity Read ↗

The correlation of EZH2 expression with the progression and prognosis of hepatocellular carcinomaSemantic proximity Read ↗

EZH2 as a prognostic-related biomarker in lung adenocarcinoma correlating with cell cycle and immune infiltratesSemantic proximity Read ↗

Analysis on EZH2: mechanism identification of related CeRNA and its immunoassay in hepatocellular carcinomaSemantic proximity Read ↗

Systematic Pan-Cancer Analysis Reveals the Prognostic Value and Immunological Role of EPHX2Semantic proximity Read ↗

EZH2 as a Prognostic Factor and Its Immune Implication with Molecular Characterization in Prostate Cancer: An Integrated Multi-Omics in Silico AnalysisSemantic proximity Read ↗

Overexpression of EZH2 is associated with clinicopathological parameters and poor prognosis in gliomasSemantic proximity Read ↗

Targeting EZH2 Reprograms Intratumoral Regulatory T Cells to Enhance Cancer ImmunitySemantic proximity Read ↗

[EZH2 is therapeutic target for personalized treatment in multiple myeloma].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.